Novo Nordisk CEO defends lawsuit against Eli Lilly: ‘Competition has to be fair’
Novo Nordisk CEO defended the company’s decision to sue rival Eli Lilly over its weight-loss drug advertising. Source link
Tag: Novo Nordisk A/S
Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline
Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo. While the experimental medicine, ziltivekimab, did show some biological effect, it didn’t translate into a statistically meaningful reduction in MACE, defined as…
Fat cat? Weight-loss drugs may be coming for your overweight pet
A beautiful, but over weight Maine Coon Cat gets measured around the belly by a vet. Ryersonclark | E+ | Getty Images Felix is five years old, loves food, and refuses to lose weight. His owner, Amy in Dallas, has tried cutting back on meals, but with two cats in the house, “he just gobbles…
Read More “Fat cat? Weight-loss drugs may be coming for your overweight pet” »
Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novo Nordisk isn’t catching a break this year. Shares of the Danish drugmaker plummeted on Monday after it released data showing that its next-generation obesity drug failed…
Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs; Hims stock falls 18%
Novo Nordisk on Monday said it is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies of the drugmaker’s new Wegovy obesity pill and injections in the U.S. Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe on the company’s patents and…
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The future of the booming obesity drug market won’t hinge on drugs that deliver greater weight loss alone. Top executives from drugmakers big and small told CNBC that the next phase…
First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Nov. 24, 2025. Tom Little | Reuters Novo Nordisk will start rolling out the first-ever GLP-1 pill for weight loss in the U.S. on Monday, the company announced, marking a new chapter of obesity…
Read More “First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. ” »
Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Novo Nordisk on Monday said it has cut the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic, adding to efforts by the company and the Trump administration to…
Read More “Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month” »
Healthy Returns: New FDA rules affect copycat GLP-1s, and Apple adds health tools to its latest Watch
FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009. Jason Reed | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The Food…
Eli Lilly’s obesity pill remains a viable rival to Novo’s oral Wegovy despite data that underwhelmed investors
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly‘s stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. In a key late-stage trial,…